Topic Hub
15 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 15 of 15 clinical reviews.
Evidence-based comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including ARCH trial head-to-head data, fracture reduction rates, and clinical guidance on sequencing.
Read clinical reviewA detailed comparison of Fosamax (alendronate) and Evenity (romosozumab) side effects, including GI tolerability, cardiovascular risk, ONJ, atypical fractures, and clinical guidance on switching.
Read clinical reviewA detailed comparison of Fosamax (alendronate) and Prolia (denosumab) covering price, insurance coverage, fracture efficacy data, and practical access considerations for osteoporosis treatment.
Read clinical reviewCompare Fosamax (alendronate) and Prolia (denosumab) for osteoporosis: fracture reduction data from FIT and FREEDOM trials, BMD gains, onset of action, and which drug fits which patient.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and denosumab (Prolia) for osteoporosis, with evidence-based guidance on when and how to switch between these two therapies.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) covering efficacy data, pricing, insurance coverage, generic availability, and practical access considerations for osteoporosis treatment.
Read clinical reviewEvidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, covering fracture reduction, BMD gains, dosing, side effects, and switching protocols.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) side effects, tolerability, and safety data from the FIT and HORIZON-PFT trials.
Read clinical reviewEvidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, including when and how to switch between these bisphosphonates.
Read clinical reviewA clinical comparison of Prolia (denosumab) and Evenity (romosozumab) side effects, cardiovascular warnings, injection-site reactions, rebound fracture risk, and monitoring requirements.
Read clinical reviewClinical comparison of denosumab and romosozumab for osteoporosis, including when and how to switch between them, trial data from FREEDOM and ARCH, and sequencing strategies to protect bone density.
Read clinical reviewA clinical comparison of the side-effect profiles of zoledronic acid (Reclast) and romosozumab (Evenity) for osteoporosis, including cardiovascular signals, acute-phase reactions, injection-site events, and rare skeletal risks.
Read clinical reviewA clinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) covering efficacy, cost, insurance coverage, generic availability, and access considerations for osteoporosis treatment.
Read clinical reviewA clinical comparison of side effects between Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including acute-phase reactions, rebound fracture risk, ONJ, and long-term safety data from HORIZON-PFT and FREEDOM trials.
Read clinical reviewClinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including when and how to switch between these two bone-loss therapies safely.
Read clinical review